Fact-checked by Grok 2 weeks ago

Essiac

Essiac is a mixture developed in the 1920s by Canadian nurse Rene Caisse as an alternative treatment for cancer, based on a traditional Ojibwa formula she claimed was shared by an Indigenous healer. It consists of four primary ingredients—burdock root (), sheep sorrel (), slippery elm inner bark (), and Turkish or Indian rhubarb root ()—prepared by boiling the herbs and taken orally as a . A related product, Flor Essence, expands on this formula by adding four more herbs: (Nasturtium officinale), blessed thistle (Cnicus benedictus), red clover (Trifolium pratense), and (Laminaria species). Caisse reportedly learned of the remedy in from a who attributed her cancer remission to it, prompting Caisse to experiment and promote Essiac despite lacking formal scientific validation. She operated a in , from 1934 to 1942, treating for free, and continued distributing the tea until her death in 1978, after selling the rights to Resperin Corporation, a Canadian company, in 1977. Throughout its history, Essiac has been marketed worldwide as a for and immune support, though formulations can vary between batches and commercial versions. Proponents claim Essiac can fight cancer by reducing tumor size, relieving pain, boosting the , and improving quality of life, with additional uses for conditions like and AIDS. However, it is not approved by the U.S. (FDA) for treating any medical condition and is regulated only as a . Scientific evaluation reveals limited evidence of efficacy. Laboratory studies have shown mixed results, such as Essiac inhibiting cell growth (2004 study) but Flor Essence increasing incidence in rats (2004 study). No peer-reviewed clinical trials demonstrate anticancer benefits in humans, with early reviews (e.g., 1938 Royal Cancer Commission, 1980s retrospective of 86 patients) finding minimal or inconclusive responses. Safety concerns include , , and potential interactions with , though it is generally considered low-risk for short-term use in healthy individuals.

History

Origins and Development

Essiac traces its roots to traditional herbal remedies used by the Ojibwa (Anishinaabe) people of , , where indigenous healers employed plant-based mixtures to treat various ailments, including conditions resembling cancer. In 1922, a Canadian nurse named Rene Caisse learned of an Ojibwa healer's formula when a she treated for credited the mixture—administered years earlier by an Ojibwa —for her recovery. This formula, comprising four herbs—burdock root (), sheep sorrel (), slippery elm inner bark (), and Indian rhubarb root ()—formed the basis of Essiac, named by Caisse as her surname spelled backward. Caisse began using the formula in the early , modifying it into oral and injectable forms. These efforts occurred amid her initial experiments in , where she first administered the to family members and select patients starting around 1924, though records of these early uses remain largely undocumented and anecdotal.

Rene Caisse's Role

Rene Caisse (1888–1978), a Canadian nurse born in , obtained an herbal formula from an Ojibwa via one of her patients in 1922 and began administering it as a treatment for cancer starting in 1924, renaming the mixture Essiac after her surname spelled backward. Working initially in Haileybury and later in other locations, she modified the formula into oral tea and injectable forms, providing it to patients including family members and others with advanced disease. In the 1950s and 1960s, Caisse collaborated with U.S. physician Dr. Charles Brusch to develop an eight-herb version of the formula, later commercialized as Flor Essence. In 1934, Caisse established a free cancer clinic at the former British Lion Hotel in , where she treated hundreds of patients until closing the facility in 1942 due to regulatory pressures. She administered Essiac without charge to many, focusing on those unable to afford conventional care, and documented patient progress through personal records and testimonials. Caisse promoted Essiac based on anecdotal reports of tumor reductions, pain relief, and remissions among her patients, attributing these outcomes to the formula's effects. These claims received endorsements from some physicians who observed her treatments, including support for its potential in managing cancer symptoms. She collaborated with medical professionals in early testing and refinement efforts during the 1920s. Throughout her career, Caisse advocated for Essiac's legalization through repeated to Canadian authorities, culminating in a 1938 petition to the bearing over 55,000 signatures from patients, physicians, and supporters seeking permission for her to treat cancer patients. This effort highlighted her persistent push for official recognition amid ongoing scrutiny from health officials.

Commercialization and Legal Challenges

In 1977, shortly before her death, Rene Caisse sold the rights to her four-herb Essiac formula to Resperin Corporation, a Toronto-based company, for a nominal $1, with the intention of enabling and broader distribution under controlled conditions. This agreement permitted Resperin to conduct limited clinical trials in and the to evaluate Essiac's safety and efficacy as a potential . However, the trials, which enrolled patients between 1978 and 1982, yielded inconclusive results, showing no significant improvements in survival rates or tumor regression, though some participants reported symptom relief. In September 1982, Health 's Health Protection Branch suspended Resperin's permission to distribute Essiac due to inadequate progress in , manufacturing inconsistencies, and failure to provide sufficient of benefit, effectively halting the trials. Throughout her career, Caisse faced significant legal for promoting and administering Essiac. In , she was arrested in for practicing medicine without a while operating her , but the charges were dropped after she agreed to treat patients only under supervision and public pressure mounted in her favor. Earlier, in 1938, the Canadian Department of National Health and Welfare classified Essiac as an unapproved drug following an by the Commission for the Investigation of Cancer Remedies, which found limited of and criticized Caisse's refusal to fully disclose the formula. These events reflected broader regulatory concerns over unproven therapies, leading to ongoing restrictions that limited Essiac's promotion and use. Following Caisse's death and the cessation of Resperin's efforts, commercial versions of Essiac proliferated despite regulatory hurdles. In the United States, Resperin filed an unsuccessful New Drug Application with the Food and Drug Administration (FDA) in the early 1980s, which deemed Essiac unproven for cancer treatment, preventing its approval as a drug. Products were instead marketed as dietary supplements, allowing international sales through health food stores and online without FDA premarket approval, though claims of treating disease remained prohibited. In Canada, authorities imposed restrictions barring cancer-related claims, confining promotion to general wellness benefits, while Essiac was briefly available via the discontinued Emergency Drug Release Program for compassionate use. A notable commercial variant emerged in the 1990s when Flora Manufacturing & Distributing Ltd. introduced Flor Essence, an eight-herb formula building on Essiac's ingredients by adding watercress (Nasturtium officinale), blessed thistle (Cnicus benedictus), red clover (Trifolium pratense), and kelp (Laminaria species). Marketed primarily as a detoxifying to support immune function, Flor Essence gained popularity in and abroad, sold by the company as a without approval for medical claims. This expansion highlighted the challenges of regulating herbal products, as variants continued to be distributed globally amid persistent legal and scientific debates over their unverified therapeutic value.

Composition

Key Ingredients

The standard four-herb formula of Essiac consists of burdock root (, traditionally used as a and blood purifier), sheep sorrel (, including leaves and roots for purported effects), slippery elm inner bark (, valued for its content that soothes the digestive tract), and Indian (or Turkish) rhubarb root (, containing anthraquinones with properties). The herbs are typically blended in proportions of approximately 52% sheep sorrel (including roots), 24% burdock root, 16% slippery elm inner bark, and 8% rhubarb root, though exact ratios may vary by producer. Variations exist in an eight-herb version, which adds ( officinale), blessed (Cnicus benedictus), clover (), and () to the original four, though this extended formula is less common in contemporary use. Sourcing and quality concerns arise with Essiac products, as unregulated supplements may contain contaminants such as or residues, potentially due to inconsistent growing, harvesting, or processing practices. Proponents of Essiac attribute potential benefits to herbal synergies, such as compounds including polyphenols in burdock root and overall immune-modulating effects from the combined , though these interactions remain unverified in rigorous studies.

Preparation Methods

The traditional preparation of Essiac involves boiling a mixture of the four primary —burdock root, sheep sorrel, slippery elm inner bark, and Turkish rhubarb root—in water to create a concentrated . To prepare approximately one gallon of , 2 ounces of the dried blend are added to 16 cups (1 gallon) of pure, filtered water in a or enamel pot, brought to a , and then simmered covered for 10 minutes. After simmering, the mixture is removed from heat and allowed to steep for 12 hours at , covered, before being reheated to steaming hot, strained through a fine mesh, and poured into dark glass or ceramic containers for refrigeration. Rene Caisse emphasized the importance of using non-reactive cookware, such as pots, to avoid contamination from aluminum or other metals, and recommended storing the prepared in dark bottles in the , where it remains potent for up to two weeks. The standard dosage for the prepared is 1/4 cup (2 ounces) diluted in 1 cup of warm water, taken twice daily on an empty stomach, ideally 30 minutes before meals or bedtime. Commercial Essiac products, often sold as pre-mixed dry teas or ready-to-use liquids, follow similar brewing protocols but may vary slightly by manufacturer. For example, Flor Essence, an eight-herb variant including the original four plus additional botanicals like red clover and blessed thistle, is available in liquid form with instructions to measure 1–2 ounces and dilute with an equal or greater amount of hot water, consumed twice daily on an empty stomach. Dry Flor Essence blends are prepared by boiling one packet (sufficient for 32 ounces) in 4 cups of water for 15–20 minutes, for 8–12 hours, straining, and refrigerating, with a recommended dosage of 3 tablespoons of the prepared three times daily. Proponents of Essiac often recommend an initial "intensification" phase of two weeks, during which the full dosage is taken three times daily to support , followed by a maintenance phase of twice-daily use. Additional guidelines include using only purified or spring water, avoiding microwaving or freezing the to preserve its properties, and consuming it promptly after preparation to maintain efficacy.

Claimed Therapeutic Uses

Traditional and Anecdotal Claims

Essiac's roots trace back to traditional Ojibwa (also known as ) medicine, where an herbal mixture purportedly similar to the modern formula was used for centuries to purify the body and treat cancer, though the authenticity of these origins and specific uses are debated. According to historical accounts, Ojibwa healers employed the blend to purify the body and restore balance. These practices were part of broader herbal traditions in , emphasizing harmony with nature for overall health maintenance. In the 1930s and , Rene Caisse, a Canadian nurse, administered Essiac to numerous patients at her Bracebridge clinic, gathering anecdotal reports of remarkable outcomes. Patients described experiences such as tumor reduction and apparent remissions in cases deemed terminal by conventional physicians. For instance, testimonials recounted relief from severe pain, improved appetite, and a renewed sense of , with one notable story involving Caisse's aunt, who reportedly survived 21 years beyond a diagnosis after using the . These narratives, shared through personal letters and clinic records, highlighted unverified stories of extended survival and vitality among users with advanced cancers. During the 1970s, as Essiac gained traction through Resperin Corporation's distribution in , alternative health newsletters and community publications featured patient testimonials emphasizing subjective benefits like enhanced levels and reduced . Users in these circles often reported feeling more vigorous and experiencing less discomfort from chronic conditions, attributing these effects to regular Essiac consumption as part of routines. Over time, Essiac has been adapted in North American folk medicine and holistic practices for purposes beyond cancer, such as and general promotion. Practitioners in communities have incorporated it into regimens aimed at cleansing the body of toxins and supporting immune function, viewing it as a gentle for everyday in line with traditional herbalism. These uses reflect its evolution into a staple of integrative traditions, often shared through word-of-mouth and community gatherings rather than formal channels. Proponents of Essiac, including its developer Rene Caisse and later commercial marketers, have primarily promoted the for its claimed anticancer effects, asserting that it detoxifies the body by removing toxins and poisons, enhances function, and reduces tumor size to prolong survival in various cancers. Secondary benefits advocated include relief from pain and side effects, improved appetite, and increased overall vitality and , with these outcomes attributed to the ' proposed and activities that neutralize free radicals and support cellular repair. In promotional literature, broader assertions encompass cleansing the blood, purging toxic build-up through synergies, and preventing diseases by promoting effective assimilation and immune balance. Dosage-dependent uses are recommended, such as short-term regimens for acute symptom relief and longer-term or continuous intake, like a 12-week program or 30–360 mL daily for adults, aimed at ongoing detoxification and prevention.

Scientific Assessment

Preclinical Research

Preclinical investigations into Essiac have focused on its potential biological activities through experiments and animal models, primarily examining cytotoxic, antiproliferative, and immunomodulatory effects on cancer-related processes. In vitro studies have reported cytotoxic effects of Essiac on select lines. A 2007 analysis demonstrated significant cell-specific cytotoxicity of Essiac toward ovarian epithelial cells (A2780 line), with activity persisting at a 20-fold dilution, linked to induction of and mechanisms. Similarly, a 2004 study found that Essiac inhibited proliferation in human cell lines while enhancing immune responses to antigenic stimulation, suggesting potential antitumor activity without notable toxicity to normal cells. More recent work in 2021 showed that exposure to Essiac liquid herbal extract reduced cell viability and proliferation in cells (K-562 line) by up to 50% at high concentrations, though this effect was not primarily driven by induction. Animal models have produced mixed outcomes regarding Essiac's impact on tumor growth and immune function. In the 1970s, multiple experiments at using mice bearing S-180 sarcomas revealed no immunostimulatory or chemotherapeutic benefits, with no inhibition of tumor progression observed across eight trials. Early 1980s studies at the same institution, involving 17 trials with and solid tumor models in mice, similarly detected no anticancer activity. A 1983 evaluation in mice with P388 lymphocytic confirmed the absence of antitumor effects, noting lethal only at elevated doses. Research on individual components has highlighted potential mechanisms underlying observed effects. Burdock root () provides polyphenols with documented anti-inflammatory properties in preclinical models, reducing inflammatory markers and in animal tissues. These findings are limited by inconsistencies across studies, often attributable to variations in extract preparation and lack of standardization. A 2021 review by emphasized Essiac's capabilities but concluded it lacks curative anticancer properties in non-human models. The National Cancer Institute's summary similarly notes conflicting results and no reproducible benefits in animal tumor inhibition or survival.

Clinical Evidence

Clinical investigations into Essiac's efficacy in humans have been limited, with no large-scale randomized controlled trials (RCTs) demonstrating anticancer benefits. Early efforts focused on small-scale evaluations, often hampered by methodological limitations such as lack of controls and incomplete data collection. A preliminary clinical study conducted in 1959 at , at the request of Rene Caisse and Dr. Charles Brusch, aimed to assess Essiac's potential activity but encountered significant difficulties with test systems, preventing definitive conclusions on tumor responses. In the 1970s, Resperin Corporation Ltd. conducted a Phase I safety trial under Canada's Emergency Drug Release Program, involving 86 terminal cancer patients who received Essiac compassionately from 1978 to 1982. The study reported no objective anticancer activity or tumor regression, though some patients experienced subjective symptom palliation, such as reduced need for analgesics in five cases and stable disease in four. A subsequent by Canada's of National Health and Welfare in the early 1980s analyzed physician reports from these 86-87 cases, finding no evidence of clinical benefit, with 47 patients showing no response, 17 deaths during , and only limited subjective improvements in a minority; permission for further distribution was withdrawn due to inadequate research protocols. More recent human data include a 2006 retrospective cohort study (TEA-BC) examining 510 women with diagnosed between 1998 and 2000, comparing Essiac users (n=51) to non-users. Health-related (HR-QOL) and mood were assessed using validated tools like the Functional Assessment of Cancer Therapy-Breast (FACT-B) and Profile of Mood States (POMS); results showed no improvements in Essiac users, with worse outcomes in physical well-being and doctor-patient relationships compared to non-users. This observational design was prone to biases, including self-selection and confounding from concurrent conventional treatments. The National Cancer Institute's summary (updated 2025) reinforces the absence of rigorous evidence, noting that laboratory, animal, and human studies collectively show no clear anticancer effects for Essiac, with all clinical data limited by small sample sizes, lack of blinding, and reliance on subjective reports rather than objective endpoints like survival or tumor shrinkage. Ongoing methodological critiques highlight these issues, alongside potential confounders such as patients' prior therapies and the absence of controls, underscoring the need for well-designed RCTs to evaluate any palliative benefits.

Regulatory Perspectives

In , regulates Essiac as a natural health product (NHP) under the Natural Health Products Regulations, which came into effect in 2004, allowing its sale for general wellness purposes such as supporting immune function or , provided no disease-specific claims are made. Products bearing a Natural Product Number (NPN) are licensed and monitored for quality, including checks for adulteration or contamination. Therapeutic claims for treating cancer or other conditions are prohibited, as Essiac lacks approval for such uses; historically, a 1967 license for supportive cancer therapy was revoked in 1982 due to insufficient evidence and non-compliance. In the United States, the (FDA) classifies Essiac as an unapproved new drug when marketed with disease treatment claims, such as curing cancer, rendering such promotions illegal under the Federal Food, Drug, and Cosmetic Act. Import restrictions imposed in the and were eased to permit personal use, but the FDA continues to issue warning letters to sellers making unsubstantiated claims; for instance, in 2017, a letter was sent to , Inc., for promoting Essiac as a . Under the Health and Education Act (DSHEA) of 1994, Essiac can be sold as a dietary supplement without pre-market approval if labeled solely for general health support, without implying treatment of specific diseases. Internationally, the regulates herbal products like Essiac under Directive 2004/24/EC, which governs traditional herbal medicinal products requiring evidence of at least 30 years of safe use (including 15 years in the EU) for registration and therapeutic claims. Essiac is typically marketed as a food supplement rather than a registered medicine, prohibiting health claims related to disease prevention or treatment to comply with EU regulations. The (WHO), in its 2019 global report on traditional and complementary medicine, emphasizes the need for evidence-based regulation of such products and highlights the risks of unproven therapies, aligning with assessments that Essiac lacks substantiation for cancer-related benefits. As of 2025, the (NCI) maintains its stance that there is no supporting Essiac for or , reiterating no endorsement and advising against its use as a substitute for proven therapies. Regulatory bodies, including the FDA and (FTC), continue to scrutinize online sales of Essiac for misleading marketing, with ongoing enforcement actions against platforms promoting it as a cancer cure without evidence.

Safety Profile

Reported Side Effects

Common mild side effects associated with Essiac use include and . According to the manufacturer of Flor Essence, a formulation similar to Essiac, additional effects may encompass increased bowel movements, , flu-like symptoms, headaches, inflamed glands, and skin rashes, often attributed to purported processes. These symptoms are generally self-limiting and occur infrequently among users. Rare severe reactions have been documented in isolated cases. For instance, a 59-year-old woman experienced anorexia, , myalgia, , and generalized after consuming Essiac , with symptoms resolving upon discontinuation. Liver toxicity has also been reported, potentially linked to the anthraquinones in turkey rhubarb root, a key ingredient; animal studies indicate risk at high doses or with long-term exposure, though human cases specific to Essiac remain limited. Allergic responses, such as skin rashes, may arise in individuals sensitive to sheep sorrel. User surveys and clinical observations provide further insight into adverse event prevalence. In a 2006 retrospective cohort study involving 510 breast cancer patients using Essiac, two individuals (approximately 0.4%) reported minor gastrointestinal upset, specifically nausea, alongside an unpleasant aftertaste; no severe events were noted. A 2021 review by Memorial Sloan Kettering Cancer Center highlighted potential for bowel inflammation based on case reports of abdominal discomfort. Factors influencing side effects include dosage and duration of use, where high or prolonged intake can amplify the laxative effects of and sheep sorrel, leading to , , and electrolyte imbalances. Vulnerable populations, such as pregnant women, face heightened risks of due to these properties, and Essiac is not recommended for them.

Potential Interactions and Contraindications

Essiac, composed of burdock root, sheep sorrel, slippery elm bark, and turkey root, may interact with certain medications due to the pharmacological properties of its ingredients. The laxatives in root can cause depletion, which may increase the risk of by exacerbating , a known potentiator of digoxin's cardiac effects. Similarly, this laxative effect could indirectly affect by promoting and potential , though evidence is less direct and primarily linked to imbalances rather than antagonism. Burdock root's mild properties may potentiate the effects of prescription diuretics, such as , leading to excessive fluid loss and , and could additively lower when combined with antihypertensives. Contraindications for Essiac use include and , as safety data are lacking and certain herbal components pose risks; for instance, variants like Flor-Essence that incorporate red clover exhibit estrogenic activity, which may act as a uterine and potentially affect fetal development or hormone-sensitive conditions. Individuals with should exercise caution or avoid Essiac due to 's high content, which can contribute to oxalate nephropathy or exacerbate kidney stone formation in susceptible patients. When used alongside chemotherapy, Essiac has been associated with pharmacokinetic interactions; a case report documented decreased clearance of the experimental topoisomerase inhibitor DX-8951f via CYP450 enzyme effects, potentially increasing drug exposure and toxicity. Essiac is contraindicated for patients with , as laboratory studies suggest it may stimulate the growth of human cells through estrogen receptor-dependent and independent pathways. Additionally, Essiac's reported nauseogenic effects may add to cisplatin-induced and , compounding gastrointestinal adverse events without established mitigation strategies. Physicians should be consulted prior to Essiac use, particularly for long-term administration, with monitoring of levels recommended to detect imbalances from 's action.

Cultural Impact

Adoption in

Essiac experienced a notable surge in popularity during the 1990s, driven by publications such as Cynthia Olsen's 1996 book Essiac: A Native Cancer Remedy, which detailed its origins and purported uses, and the emergence of early forums where users shared personal experiences. This period coincided with growing interest in remedies, making Essiac particularly appealing to holistic cancer support groups seeking non-conventional options alongside emotional and community-based care. In contemporary , Essiac has been integrated into integrative practices, often recommended as a complementary to conventional treatments in wellness centers focused on holistic patient support. It is commonly available through health food stores, with U.S. exceeding $8 million annually by 2001, reflecting sustained market demand. Demographic trends indicate primary use among adherents of ; for instance, a survey of patients found that 6.2% reported using Essiac, typically those exploring supportive outside mainstream protocols. Its global reach has expanded through exports to regions including and , where it is marketed as a in markets. Modern formulations have evolved beyond traditional teas, including capsule versions and enhanced blends such as Essiac Gold, which incorporates active hexose correlated compound (AHCC) from mushrooms and is promoted for general support in contexts beyond cancer care. These variants cater to broader consumer preferences for convenient, non-liquid options while maintaining the core composition.

Ongoing Controversies

Essiac has long been criticized for potentially exploiting the desperation of cancer patients seeking unproven cures, with organizations highlighting how its promotion preys on hope without scientific backing. The notes that since the 1930s, Essiac's claims have sparked controversy, including disputes over its efficacy that led to the closure of Rene Caisse's clinic in 1942 amid regulatory scrutiny. Critics, including references to evaluations by the , have labeled it ineffective for , emphasizing ethical issues in marketing it as a viable to conventional therapies. Promotional controversies center on unsubstantiated claims and legal actions against sellers. In 2008, the initiated enforcement actions against multiple companies, including those marketing , for deceptive that falsely promised cancer cures and other benefits, resulting in settlements prohibiting such claims. Debates over secrecy and authenticity intensified after Caisse's death in 1978, when she transferred rights to ; however, variations emerged, with the original four-herb blend differing from eight-herb versions like Flor Essence, and multiple manufacturers producing similar products without verified adherence to the purported original recipe, as documented in legal affidavits like Mary McPherson's . Scientific skepticism arises from accusations that proponent literature relies on anecdotal reports and selective data, contrasting with rigorous reviews finding no robust . A 2009 systematic review by the Natural Standard Research Collaboration graded Essiac's efficacy for cancer as C, indicating conflicting or limited-quality , primarily from and rather than human trials. The Cancer Institute's summary, last updated in April 2025, confirms no randomized controlled trials exist to support Essiac's anticancer claims, with preclinical data showing mixed results, such as potential effects but no consistent tumor reduction .

References

  1. [1]
    Essiac/Flor Essence (PDQ®)
    ### Summary of Essiac and Flor Essence
  2. [2]
    Essiac Tea: Is It Good For You? - WebMD
    In 1922, nurse Rene Caisse first introduced essiac tea to the world. She presented it as an alternative treatment for cancer. The story goes that she had a ...Missing: composition efficacy
  3. [3]
    Essiac/Flor Essence - NCI - National Cancer Institute
    May 28, 2024 · Essiac and Flor Essence are herbal tea mixtures that have been used as anticancer treatments. They have been used to treat other health conditions.Missing: composition efficacy
  4. [4]
    [PDF] Chapter 4 - Herbal Treatments - Princeton University
    Rene Caisse began her career as a public health nurse in Haileybury, Ontario. In 1922, one of. Caisse's patients told her that she had recovered from breast ...
  5. [5]
    Essiac/Flor Essence (PDQ®) - NCBI - NIH
    Apr 23, 2003 · Essiac/Flor Essence are herbal tea mixtures that are marketed worldwide as dietary supplements, and sometimes used by cancer patients.
  6. [6]
    None
    ### Summary of Historical Facts About Rene Caisse and Essiac
  7. [7]
    [PDF] Transformation Series - à www.publications.gc.ca
    Essiac was high in the 1930s (55,000 signed petitions in support in the 1930s)34 but dimmed, as did that for most alternative medicine, in the postwar ...
  8. [8]
    [PDF] i was canada's cancer nurse
    1938. BILL. An act to authorize Rene Caisse to practise medicine in the province of Ontario in the treatment of Cancer and conditions resulting therefrom.
  9. [9]
    [PDF] Unconventional therapies for cancer: 1. Essiac - CMAJ
    For 40 years Rene Caisse gave Essiac to several hun- dreds of cancer patients. She reportedly administered one of the herbs by injection and the others as a ...Missing: Sharpe | Show results with:Sharpe
  10. [10]
    [PDF] Unconventional Cancer Treatments - Center for Inquiry
    ... Health and Life Sciences Division. Clyde J. Behney, Health Program Manager. Project Staff. Hellen Gelband, Project Director. Julia T. Ostrowsky, Principal ...
  11. [11]
    Effect of aqueous extract of Arctium lappa L. (burdock) roots on the ...
    Feb 1, 2012 · root is traditionally used in herbal remedies to treat tonsillitis, throat pain, arthritis, rashes, and various skin problems, and as a diuretic ...
  12. [12]
    Slippery Elm - LiverTox - NCBI Bookshelf
    Jan 5, 2024 · Slippery elm preparations were used in Native American traditional medicine for gastrointestinal and urinary tract disorders and topically for ...Missing: soothing | Show results with:soothing
  13. [13]
    What we already know about rhubarb: a comprehensive review - PMC
    Aug 26, 2020 · The combination of anthraquinones in rhubarb play a role in inducing diarrhea, while tannic acid can inhibit the laxative effect of ...
  14. [14]
    Heavy Metal and Pesticide Content in Commonly Prescribed ... - NIH
    Several studies have shown that CHMs and other botanical supplements may be contaminated with heavy metals, and in some cases at toxic levels (Ernst, 2002; ...Missing: Essiac | Show results with:Essiac
  15. [15]
    Heavy metals in traditional Indian remedies | Request PDF
    Aug 6, 2025 · Humans are subject to contamination by heavy metals by ingesting both homemade and industrial plants or teas. ... Other contaminants used are ...<|control11|><|separator|>
  16. [16]
    Burdock Root: Benefits, Side Effects, and More - Healthline
    Feb 6, 2024 · Burdock root has been shown to contain multiple types of powerful antioxidants, including quercetin, luteolin, and phenolic acids ( 2Trusted ...
  17. [17]
    Essiac Tea: Ingredients, Benefits and Side Effects - Healthline
    Nov 28, 2018 · In the 1920s, Canadian nurse Rene Caisse promoted Essiac tea as a natural cancer treatment, claiming that it was given to her by a patient ...Missing: Sharpe | Show results with:Sharpe
  18. [18]
    How to Make Essiac Tea - Blue Moon Herbs / Rene Caisse Tea
    The basic process for making Essiac tea decoction involves a 10-12 hour steeping time. The herbs are boiled, covered, for 10 mins., left to steep at room ...
  19. [19]
    https://renecaissetea.com/essiac-information/how-to-make-essiac-tea/
  20. [20]
    Flora Flor-Essence® 7-Day Purification Program -- 1 Kit - Vitacost
    In stock Rating 5.0 (2) Flor-Essence: Adults: Shake well before use Measure 1-2 oz and dilute with an equal or greater amount of hot water. Take twice daily, preferably 30 minutes ...
  21. [21]
    Check Out Our Easy Essiac Tea Brewing Instructions
    Add 1/2 oz. (14 grams) of the Essiac herbs blend. It's best to weigh the herbs, but a heaping 1/4 dry measurement cup is an estimate.
  22. [22]
    Essiac | Research Starters - EBSCO
    Essiac is an herbal mixture that originated from the Ojibwa people in Canada and is traditionally used for addressing cancerous tumors.Missing: evolution eight historical
  23. [23]
    [PDF] Rene Caisse - The Essiac Council
    Mali Klein is the founder of Clouds Trust and co-author of Essiac Essentials and The. Secrets of Rene Caisse's Herbal Pharmacy with Sheila Snow. Sheila worked ...
  24. [24]
    Essiac - Memorial Sloan Kettering Cancer Center
    Feb 25, 2021 · Tell your healthcare providers about any dietary supplements you're taking, such as herbs, vitamins, minerals, and natural or home remedies.Missing: evolution historical source
  25. [25]
    In vitro analysis of the herbal compound Essiac - PubMed
    Background: Despite the recommendation of the Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative, little research has been ...Missing: synergies polyphenols burdock
  26. [26]
    Inhibition of prostate cancer-cell proliferation by Essiac - PubMed
    Conclusions: Essiac preparations may be able to inhibit tumor cell growth while enhancing immune response to antigenic stimulation. This may be especially ...Missing: apoptosis | Show results with:apoptosis
  27. [27]
    Investigation of the in vivo and in vitro effects of Essiac® liquid ...
    Therefore, in this study using the fully-prepared proprietary blend, Essiac® Liquid Herbal Extract (LHE), we thoroughly explored its health benefits using the ...
  28. [28]
    [PDF] Investigation of the in vivo and in vitro effects of Essiac® liquid ...
    Jan 25, 2021 · In vitro studies exploring Essiac's® health benefits have also demonstrated it to have strong antioxidant abilities [14-16], anti-inflammatory [ ...Missing: Toronto | Show results with:Toronto
  29. [29]
    Burdock (Arctium lappa L.) root attenuates preneoplastic lesion ...
    Indeed, the bioactive compounds of A. lappa root, as the polyphenols, have already showed antioxidant and anti-inflammatory properties in different in vivo and ...
  30. [30]
    Trial of Essiac to ascertain its effect in women with breast cancer ...
    Essiac does not appear to improve HR-QOL or mood states. Future studies are needed to determine whether other clinical outcomes, such as cancer reoccurrence ...Missing: classification 1938 unapproved
  31. [31]
    (PDF) Trial of Essiac to Ascertain its Effect in Women with Breast ...
    PDF | Breast cancer is a major cause of morbidity, mortality, and medical expenditures among women in Canada. Essiac (Resperin Canada Limited, Waterloo,.Missing: Corporation halted
  32. [32]
    Search licensed natural health products - Canada.ca
    Nov 21, 2024 · Note - The market status of a product is now available in the LNHPD and identifies if a product is "marketed" or "not marketed" in Canada.Missing: Essiac | Show results with:Essiac
  33. [33]
    Sunstone, Inc. - 513214 - 04/17/2017 - FDA
    Apr 17, 2017 · Based on the labeling claims on your website, your marketed products, Essiac Tea, Premium Organic, 8 oz., and Virxcan-X Salve, are drugs under ...
  34. [34]
    WHO global report on traditional and complementary medicine 2019
    Jun 4, 2019 · This report reviews global progress in T&CM over the past two decades and is based on contributions from 179 WHO Member States.
  35. [35]
    Illegally Sold Cancer Treatments - FDA
    Nov 1, 2017 · The products are marketed and sold without FDA approval, most commonly on websites or social media platforms. They have not been reviewed by FDA ...Missing: 1982 court case
  36. [36]
    Rhubarb - Memorial Sloan Kettering Cancer Center
    Nov 8, 2022 · Animal studies suggest the potential for liver toxicity at high doses and with long-term use. Rhubarb is also a component of Essiac tea.
  37. [37]
    Rhubarb - Uses, Side Effects, And More - WebMD
    Low potassium levels can increase the risk of digoxin side effects. Medications for inflammation (Corticosteroids) interacts with Rhubarb. Rhubarb is a type of ...
  38. [38]
    https://www.mskcc.org/cancer-care/integrative-medicine/herbs/rhubarb
  39. [39]
    6 Health Benefits of Burdock Root, Backed by Science
    Aug 17, 2025 · Burdock root is a vegetable with antioxidant and anti-inflammatory effects. It may have benefits for digestive, heart, and skin health.
  40. [40]
    Burdock: Everything You Need to Know - Verywell Health
    Taking burdock with other diuretics, such as Lasix (furosemide), may cause dehydration. Cancer medicines cisplatin, quercetin, and tamoxifen: Arctigenin, a ...
  41. [41]
    Red Clover Uses, Benefits & Dosage - Drugs.com
    Nov 20, 2024 · Pregnancy / Lactation​​ Avoid use. The estrogenic effects of red clover are well documented and may have an effect on the fetus.Missing: Essiac variant
  42. [42]
    Acute kidney injury after ingestion of rhubarb: secondary oxalate ...
    Oct 30, 2012 · We report a rare case of acute secondary oxalate nephropathy, likely due to excessive ingestion of rhubarb in an adult with preexisting mild ...Missing: contraindication | Show results with:contraindication
  43. [43]
    Supplement/Botanical Interactions with Chemotherapy and Radiation
    Essiac tea is contraindicated in patients with breast cancer. Rhodiola and vitamin A should be used with caution during radiation therapy. St. Johns wort ...
  44. [44]
    Essiac therapy - Cancer Research UK
    A Canadian nurse called Rene Caisse created Essiac. She named the remedy after herself. Essiac is her surname spelled backwards. A commercial company now ...Missing: Sharpe | Show results with:Sharpe
  45. [45]
    Essiac: A Native Herbal Cancer Remedy - Cynthia B. Olsen
    Essiac: A Native Herbal Cancer Remedy. Front Cover. Cynthia B. Olsen. Kali Press, 1996 - Health & Fitness - 119 pages. This book gives a complete account of the ...
  46. [46]
    Cancer Quackery: The Persistent Popularity of Useless, Irrational ...
    Aug 20, 2012 · Unproven Oral Treatments. Essiac. Dietary supplements and herbal remedies, typically unstudied or disproved, are commonly used by cancer ...
  47. [47]
    [PDF] Trial of Essiac to Ascertain Its Effect in Women with Breast Cancer ...
    rubra]), has become one of the more popular herbal remedies for breast- cancer treatment, secondary prevention, improving quality of life, and controlling ...Missing: evolution | Show results with:evolution
  48. [48]
    Effect of Essiac on Women with Breast Cancer Examined
    Most of the women (75%) purchased the ESSIAC brand with a four herb blend and 17% purchased Flor-Essence with an eight herb blend. The average daily dose was ...
  49. [49]
    https://www.herbalgram.org/resources/herbclip/issues/2007/bin_342/review44981/
  50. [50]
    Essiac Gold® with AHCC® – Premium Immune System Booster – 60 ...
    OUR MOST POWERFUL IMMUNE SUPPORT – Essiac Gold is an organic and wild crafted herbal remedy that helps support the immune system and normalize the body by ...
  51. [51]
    Questionable Cancer Therapies | Quackwatch
    Dec 17, 2018 · Several case reviews have found no benefit for the treatment of cancer in humans. In response to political pressure, a clinical trial was begun ...
  52. [52]
    Essiac: systematic review by the natural standard research ...
    The objective of this study was to evaluate the scientific evidence on the safety and efficacy of Essiac. This review serves as a clinical support tool.Missing: skepticism cherry- picking RCTs